Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Hold on to your seat.. something big happening here!

<< Previous

Bullboard Posts

Next >>

Comment by Looking4Doubleson Jul 01, 2020 10:13am

170 Views

Post# 31211879

RE:RE:RE:RE:Hold on to your seat.. something big happening here!

Newinvestor68 wrote: There is nothing new. Same recycled message with nothing concrete

Well, I saw a change !

First announcement said: " Salzman Group will grant to Kalytera a license to commercialize R-107 for treatment of COVID-19 in Canada."

The latest one says: " Upon closing of the first part of the Acquisition Transaction, Kalytera will acquire from Salzman Group an exclusive, worldwide license to develop and commercialize R-107 for treatment of coronavirus and COVID-19 "

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record